MAGAININ PHARMACEUTICALS INC
5, 1998-02-13
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: MAGAININ PHARMACEUTICALS INC, 5, 1998-02-13
Next: MAGAININ PHARMACEUTICALS INC, 5, 1998-02-13



<PAGE>   1
                                               ---------------------------
                                                      OMB APPROVAL        
                                               ---------------------------
- ------                                            OMB Number: 3235-0362   
FORM 5                                         Expires:  September 30, 1998
- ------                                          Estimated average burden  
                                               hours per response .... 1.0
                                               ---------------------------

/ / CHECK BOX IF NO             UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    LONGER SUBJECT TO                       WASHINGTON, D.C. 20549     
    SECTION 16. FORM                                                           
    4 OR FORM 5             ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
    OBLIGATIONS MAY                                                            
    CONTINUE. SEE            Filed pursuant to Section 16(a) of the Securities 
    INSTRUCTION 1(b)         Exchange Act of 1934, Section 17(a) of the Public 
/ / FORM 3 HOLDINGS          Utility Holding Company Act of 1935 or Section
    REPORTED                 30(f) of the Investment Company Act of 1940 
/ / FORM 4                    
    TRANSACTIONS                                   
    REPORTED                                                                   

<TABLE> 
<S>                             <C>           <C>                        <C>                <C>          <C>            <C>   
- ------------------------------------------------------------------------------------------------------------------------------------
 1. Name and Address of Reporting Person*     2. Issuer Name and Ticker or Trading Symbol   6. Relationship of Reporting Person(s)
Wyngaarden        James               B.            Magainin Pharmaceuticals Inc. - MAGN            to Issuer (Check all applicable)
- ---------------------------------------------------------------------------------------------    x  Director         10% Owner
  (Last)          (First)          (Middle    3. IRS or Social Security  4. Statement for      ----              ---
c/o Magainin Pharmaceuticals Inc.               Number of Reporting        Month/Year             Officer (give      Other (specify
5110 Campus Drive                             Person (Voluntary)              12/97            ----        title ---       below)
- -------------------------------------------                               -------------------               below)
                 (Street)                                                5. If Amendment,    7. Individual or Joint/Group Reporting
                                                                            Date of Original          (Check applicable line)
                                                                            (Month/Year)         x  Form Filed by One Reporting
                                                                                                ----  Person
                                                                                                    Form Filed by More than One
Plymouth Meeting,    PA              19462                                                      ----  Reporting Person
- -------------------------------------------    -------------------------------------------------------------------------------------
  (City)           (State)           (Zip)     TABLE I -- NON-DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED
- ------------------------------------------------------------------------------------------------------------------------------------
 1. Title of Security           2. Trans-   3. Transac-  4. Securities Acquired (A)  5.  Amount of Se-    6. Owner-      7. Nature  
    (Instr. 3)                     action      tion         or Disposed of (D)           curities Benefi-    ship           of In-  
                                   Date        Code         (Instr. 3, 4 and 5)          cially Owned at     Form:          direct  
                                  (Month/      (Instr. 8)                                end of Issuer's     Direct         Benefi-
                                   Day/                                                  Fiscal Year         (D) or         cial
                                   Year)                ----------------------------     (Instr. 3 and 4)    Indirect       Owner-
                                                        Amount    (A) or      Price                          (I)            ship   
                                                                  (D)                                        (Instr. 4)     (Instr.
                                                                                                                            4)     

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                     

*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
</TABLE>

<PAGE>   2
<TABLE>
<CAPTION>
 
FORM 5 (CONTINUED)        TABLE II -- DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED
                                  (E.G., PUTS, CALL, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)

<S>                       <C>          <C>        <C>         <C>              <C>             <C>                   <C>          
- ------------------------------------------------------------------------------------------------------------------------------------
1. Title of Derivative    2. Conver-   3. Trans-  4. Trans-   5. Number of     6. Date Exer-   7. Title and Amount   8. Price 
   Security                  sion of      action     action      Derivative       cisable and     of Underlying         of     
   (Instr. 3)                Exercise     (Month/    Code        Securities Ac-   Expiration      Securities            Deriv- 
                             Price of     Day/      (Instr. 8)   quired (A) or    Date            (Instr. 3 and 4)      ative  
                             Deriv-       Year)                  Disposed of (D)  (Month/Day/                           Secur-  
                             ative                              (Instr. 3, 4,    Year)                                 ity       
                             Security                            and 5)                                                 (Instr. 5)
                                                                               -----------------------------------             
                                                                               Date    Expira-            Amount or            
                                                               --------------- Exer-   tion       Title   Number of            
                                                                (A)     (D)    cisable Date               Shares               
- ------------------------------------------------------------------------------------------------------------------------------------
Option to buy                $7.630       5/7/97       A         5,000         5/7/98+ 5/7/2007   Common  5,000            0
                                                                                                  Stock

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- ------------------------------------------------------------------------------------------------------------------------------------

- -------------------------------------------------------------------------------------------------------
<C>                    <C>                         <C>
9. Number of           10. Ownership               11. Nature of
   Derivative              of Derivative               Indirect
   Securities              Security:                   Beneficial
   Beneficially            Direct (D)                  Ownership
   Owned at End            or Indirect (l)             (Instr. 4)
   of Year                 (Instr. 4)
   (Instr. 4)
- -------------------------------------------------------------------------------------------------------
   5,000                   D
- -------------------------------------------------------------------------------------------------------

- -------------------------------------------------------------------------------------------------------

- -------------------------------------------------------------------------------------------------------

- -------------------------------------------------------------------------------------------------------

- -------------------------------------------------------------------------------------------------------

- -------------------------------------------------------------------------------------------------------
Explanation of Responses:

+ Options exercisable at the rate of 25% of such option on each of the first four anniversary
  dates of the date of grant, which was May 7, 1997.
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations.      /s/ James B. Wyngaarden     2/11/98
  See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).                                                ------------------------------- -------
                                                                                            **Signature of Reporting Person   Date


Note: File three copies of this Form, one of which must be manually signed.
      If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless 
the form displays a currently valid OMB Number.

</TABLE>

                                                  Page 2




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission